Abstract
Question What is the median time to clearance of SARS-CoV-2 among cancer patients according to currently used criteria?
Findings In this single-institution retrospective cohort study, the median time to SARS-CoV-2 clearance was 50 days using the ASCO/CDC criteria of 2 negative RT-PCR assays >24 hours apart. Using alternative criteria of 1 negative RT-PCR assay (UK-NICE) or CDC clinical criteria (10 days after first positive RT-PCR and 3 days after last symptoms), median clearance times were 31 days and 13 days, respectively.
Meaning SARS-CoV-2 clearance times differ substantially depending on criteria used and may be prolonged in cancer patients.
Background
COVID-19 in oncologic patients presents a clinical dilemma given the competing priorities of providing timely anti-cancer therapy, avoiding immunosuppression during COVID-19 infection, and minimizing exposure risk to others. Several different criteria for COVID-19 clearance have been proposed.1–3 However, the time to clearance for cancer patients under each of these criteria is not established.
Methods
We identified all patients at a tertiary care hospital between March 25, 2020 and June 6, 2020 with a positive nasopharyngeal SARS-CoV-2 RT-PCR, a cancer-related clinical visit within 3 years, and at least one follow-up SARS-CoV-2 assay. Data collection was performed as part of an institutional COVID-19 registry project and approved by the institutional review board.
SARS-CoV-2 RT-PCR testing was performed using the Abbott Laboratories m2000 platform in conjunction with either the Aldatu Biosciences PANDAA qDxTM SARS-CoV-2 or Abbott RealTime SARS-CoV-2 assays. At our institution, and per current ASCO guidelines, discontinuation of COVID-19 precautions requires two consecutive negative PCR tests >24 hours apart. Time to COVID-19 clearance was analyzed using the Kaplan-Meier probability estimator, for which data was censored at the time of the last known COVID-19 RT-PCR assay.
Results
We identified 32 patients who met inclusion criteria (Supplementary Figure S1). Patient and tumor characteristics are described in Table 1. 16 patients had metastatic disease at the time of COVID-19 diagnosis. 17 patients were on active treatment at the time of COVID-19 diagnosis, 8 receiving cytotoxic chemotherapy.
Baseline patient characteristics Median Age
Using our institutional criteria, 13 patients were cleared of COVID-19 precautions, at a median time of 33 days (range 10-58 days) (Figure 1). Across the full cohort, median time to clearance was estimated at 50 days (95% CI, 33-58 days) (Figure 2). 14 patients resumed anti-cancer treatment prior to clearance, requiring substantial allocation of resources for isolation during treatment. All patients were asymptomatic from COVID-19 at the time of resuming anti-cancer treatment, and experienced no subsequent complications attributable to COVID-19. Among the 13 patients who met clearance criteria, 2 subsequently had a positive RT-PCR test.
(+) indicates SARS-CoV-2 positive RT-PCR from a nasopharyngeal specimen. (-) indicates SARS-CoV-2 negative RT-PCR. Orange bars indicate patients who were cleared during the follow-up period based on 2 negative RT-PCR results >24 hours apart. Patients #21 and #26 later had a subsequent positive SARS-CoV-2 PCR after meeting clearance criteria.
Kaplan-Meier probability estimate functions are shown for three alternative criteria for defining COVID-19 precaution clearance: A) ASCO/CDC test-based guideline of 2 negative RT-PCR results > 24 hours apart, B) UK-NICE guideline of 1 negative RT-PCR after the initial COVID-19 diagnosis, and C) revised CDC symptom-based recommendations for clearance. In panels A and B, patients are censored at time of last SARS-CoV-2 PCR assay. In panel C but no censoring was needed as all patients achieved clearance at last clinical follow-up.
We calculated COVID-19 clearance times under alternative criteria. Using the UK-NICE guidelines (one negative RT-PCR test), median time to clearance would have been 31 days (95% CI, 26-42 days). Using a symptom/time-based strategy per CDC criteria (10 days after first positive RT-PCR and 3 days after last symptoms), median time to clearance would have been 13 days (95% CI, 10-17 days) (Figure 2). Cox proportional hazards models showed that patients with symptoms from COVID-19 versus those asymptomatically detected had longer time to first negative RT-PCR (HR 0.25 for negative PCR, 95% CI 0.08-0.76, p=0.01). No significant associations were seen between anti-cancer treatment before or during COVID-19 positivity and clearance time (data not shown).
Discussion
In this study, we observe that time to nasopharyngeal SARS-CoV-2 RNA clearance in our oncology patients is substantially longer than the approximately 17-20 days previously reported in the general population.4–6 The calculated time to COVID-19 clearance varies widely under the three clinical criteria examined. Choosing criteria for COVID-19 clearance in cancer patients must take into account the tradeoffs between the increased risk of poor clinical outcomes from COVID-19, the clinical risk from delays in anti-cancer therapy, and the risk of exposing others.7,8 In addition, further elucidation of the relationship between viral shedding and infectivity is needed to guide the development of future guidelines.
Conclusions
In patients with cancer who develop COVID-19 infection, viral shedding can persist for many weeks after disease onset. Symptom/time-based strategies result in shorter times to discontinuation of precautions and resumption of treatment compared to test-based strategies, though the risks of earlier return to routine cancer care remain unclear.
Data Availability
Blinded data available for review on request
Funding
The work was partially funded by National Institutes of Health/National Cancer Institute grants K08 CA248473 (MLBP) and R37 CA218707 (DBC).
Disclosure of Potential Conflicts of Interest
JMP
Received honoraria from Radius, research grant support from Breast Cancer Research Foundation, institutional research support from Genentech, Sanofi, Odonate Therapeutics, all outside submitted work.
DBC
Reports personal fees (consulting fees and honoraria) and nonfinancial support (institutional research support) from Takeda/Millennium Pharmaceuticals, and AstraZeneca, and Pfizer, as well as nonfinancial support (institutional research support) from Merck Sharp and Dohme Corporation, Merrimack Pharmaceuticals, Bristol-Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals and Tesaro, all outside the submitted work.
MLBP
Received honoraria from Bayer, Exelixis and Agios, travel support from Halozyme, AstraZeneca and Exelixis, research support from Bayer, institutional research support from Taiho, AstraZeneca, BeiGene, Berg, Merck, all outside the submitted work.
Acknowledgments
We would like to acknowledge the clinical staff, nurses, fellows and faculty assigned to our COVID-19 outpatient/inpatient unit (HO-REEES), and our patients with a diagnosis of cancer that were afflicted during the COVID-19 pandemic.